Rasagiline Tablet
NDC Package 83085-007-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Rasagiline (rasagiline mesylate) tablets is rasagiline is used alone or with other medications (such as levodopa/carbidopa) to treat symptoms of Parkinson's disease. This formulation utilizes a tablet delivery system. Marketed by Skg Pharma Inc., this product is identified by NDC 83085-007 and is authorized under FDA application ANDA218163.

Identification & Billing

NDC Package Code
83085-007-30
Package Description
30 TABLET in 1 BOTTLE
Product Code
83085-007
11-Digit Billing Format
83085000730
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Rasagiline
Non-Proprietary Name
Rasagiline Mesylate
Substance Name
Rasagiline Mesylate
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
RASAGILINE MESYLATE .5 mg/1
Pharmacologic Class
Usage Information
Rasagiline is used alone or with other medications (such as levodopa/carbidopa) to treat symptoms of Parkinson's disease. It can help improve symptoms such as shakiness, stiffness, and difficulty moving. It can also help reduce the amount of "off" time (periods of slow movement or stiffness). Rasagiline belongs to a class of drugs known as MAO inhibitors. It works by increasing the levels of certain natural substances in the brain (such as dopamine, norepinephrine, serotonin). Parkinson's disease is thought to be caused by too little dopamine in the brain.

Regulatory & Marketing

Labeler Name
Skg Pharma Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA218163
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-04-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (83085-007). Click a package code to view its specific billing and regulatory data.

83085-007-10
1000 TABLET in 1 BOTTLE
83085-007-50
500 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 83085-007-30 identifies a specific commercial package of 30 tablet in 1 bottle of Rasagiline, a human prescription drug labeled by Skg Pharma Inc.. This tablet is formulated for oral use and contains rasagiline mesylate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Skg Pharma Inc. on April 04, 2025. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Rasagiline is used alone or with other medications (such as levodopa/carbidopa) to treat symptoms of Parkinson's disease. It can help improve symptoms such as shakiness, stiffness, and difficulty moving. It can also help reduce the amount of "off" time (periods of slow movement or stiffness). Rasagiline belongs to a class of drugs known as MAO inhibitors. It works by increasing the levels of certain natural substances in the brain (such as dopamine, norepinephrine, serotonin). Parkinson's disease is thought to be caused by too little dopamine in the brain.

How is this Skg Pharma Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 83085000730. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
83085-007-30
11-Digit CMS (5-4-2)
83085-0007-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.